Analysis: FDA Advisory Committee Snubs MDMA-Assisted Therapy for PTSD in Overwhelming “No” Vote

Last Tuesday, the FDA’s Psychopharmacologic Drugs Advisory Committee (PDAC) met to discuss Lykos Therapeutics’ MDMA-assisted therapy for PTSD New Drug Application (NDA). The meeting, which at nine hours long was only slightly lengthier than an MDMA administration session, was one of the most closely-watched Advisory Committees (AdComms) to date, with more than a thousand people tuning in to the…

Source